The best indicator for Zimmer Biomet (ZBH)
We backtested 20 indicators across daily, weekly and hourly charts on real Zimmer Biomet (ZBH) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
WaveTrend (8/6/4)
On the daily chart, this is the strongest risk-adjusted edge we found for Zimmer Biomet (ZBH) over ~24.8 years — beating buy-and-hold by 1.6% CAGR.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | WaveTrend (8/6/4) ✓ | Daily | 6.6% | 0.42 | -55.7% | 72.2% | 97 | 1.6% |
| 2 | Stochastic ✓ | Weekly | 5.5% | 0.39 | -42.5% | 79.2% | 24 | 0.2% |
| 3 | CCI ✓ | Daily | 4.7% | 0.34 | -51.4% | 74.6% | 118 | -0.4% |
| 4 | Money Flow Index ✓ | Daily | 3.8% | 0.33 | -41.7% | 78.9% | 19 | -1.3% |
| 5 | Stochastic ✓ | Daily | 3.6% | 0.28 | -60.3% | 72.4% | 127 | -1.5% |
| 6 | Williams %R ✓ | Daily | 3.5% | 0.27 | -62.9% | 71.5% | 158 | -1.6% |
| 7 | Donchian Breakout ✓ | Weekly | 2.5% | 0.24 | -45.4% | 36.8% | 19 | -2.8% |
| 8 | Holy Grail Confluence ✓ | Daily | 2.6% | 0.23 | -46.8% | 72.5% | 40 | -2.5% |
| 9 | Bollinger Mean-Reversion ✓ | Weekly | 2.4% | 0.23 | -50.8% | 77.3% | 22 | -2.8% |
| 10 | Williams %R ✓ | Weekly | 2.3% | 0.21 | -53.0% | 80.0% | 30 | -2.9% |
| 11 | SMA 50/200 Cross | Daily | 1.2% | 0.16 | -69.2% | 29.4% | 17 | -3.9% |
| 12 | ADX / DMI | Weekly | 0.9% | 0.14 | -40.2% | 47.5% | 40 | -4.3% |
| 13 | EMA 50/200 Cross | Daily | 0.7% | 0.13 | -66.7% | 27.8% | 18 | -4.3% |
| 14 | Holy Grail Confluence ✓ | Weekly | 2.1% | 0.21 | -58.8% | 77.8% | 9 | -3.1% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For Zimmer Biomet (ZBH), WaveTrend (8/6/4) on the daily timeframe gave the best balance of return and risk in our test. It beat buy-and-hold — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.